From Medscape Oncology

Coverage from the

European Hematology Association (EHA) 2024 Annual Meeting

June 13 - 16, 2024; Madrid, Spain and Virtual/Online

June 13 - 16, 2024 Madrid, Spain and Virtual/Online

Conference News

EHA 2024 Hemophilia: Marstacimab Sustains Long-Term Bleeding Decrease
MDedge News, June 28, 2024
EHA 2024 Dual CAR-T Therapies Are Becoming More Established
Medscape Medical News, June 26, 2024

EHA 2024 DLBCL: Glofitamab Plus Chemo Boosts Survival
MDedge News, June 21, 2024
EHA 2024 APL: Should Chemo-Free Regimen Become New Standard?
MDedge News, June 21, 2024

Medscape Oncology©

Perspectives

Myelofibrosis Highlights From EHA 2024
Alessandro Maria Vannucchi, MD

Popular News From EHA 2023

Novel Drug Shows 'Impressive' Efficacy in Polycythemia Vera Rusfertide, a first-in-class mimetic of hepcidin, shows high efficacy in the treatment of erythrocytosis polycythemia vera, with substantial improvements in hematocrit levels.
Medscape Medical News, Jun 20, 2023
CLL: Venetoclax-Obinutuzumab Combo Effective Long Term Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.
Medscape Medical News, Jun 20, 2023

Previous Coverage

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.